Searched for
DOMESTIC FORMULATION ASSETS
Beauty's back-end gets investor attention; Naturis in talks to raise Rs 100 croreInvestors are increasingly backing India's beauty and personal care manufacturing sector, moving beyond consumer brands. Companies like Nat...- Dalmia Bharat plans to raise Rs 4,000 cr; targets 110-130 MTPA cement capacity by FY31Dalmia Bharat is set to raise up to Rs 4,000 crore to fuel its ambitious expansion, aiming to reach 110-130 million tonnes per annum cement...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoYNatco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...
- Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Weaponised dependency: Chinese mercantilism is more damaging to global trade than Trump tariffsThe recent US-China summit saw improved engagement but little progress on global economic challenges. China's trade practices continue to i...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Motilal Oswal trims HDFC Bank, increases weight in SBI amid latest reshuffle. Here’s the full listMotilal Oswal reshuffled its model portfolio, increasing SBI weight while trimming HDFC Bank. It added stocks across financials, new-age, d...
- Panacea Biotec sells domestic formulation assets to Mankind Pharma for Rs 1,908 crorePanacea said it expects to complete the transaction by the end of this year.
- Piramal Health open to buysIt will take another six months to identify the right investment targets, Ajay Piramal, chairman, Piramal Healthcare told, referring to the...
- Religare puts 'buy' on Piramal Healthcare; target Rs 412Religare Research has maintained ‘buy’ on Piramal Healthcare for a target price of Rs 412, which is based on 16x FY10E earnings, in line wi...
- Religare puts 'buy' on Piramal Healthcare; target Rs 412Religare Research has maintained ‘buy’ on Piramal Healthcare for a target price of Rs 412, which is based on 16x FY10E earnings, in line wi...
Load More
